Cargando…

A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial

BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkh...

Descripción completa

Detalles Bibliográficos
Autores principales: Dehnavi, Sajad, Azad, Farahzad Jabbari, Hoseini, Reza Farid, Moazzen, Nasrin, Tavakkol-Afshari, Jalil, Nikpoor, Amin Reza, Salmani, Amir Abbas, Ahanchian, Hamid, Mohammadi, Mojgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611180/
https://www.ncbi.nlm.nih.gov/pubmed/31333730
http://dx.doi.org/10.4103/jrms.JRMS_543_18
_version_ 1783432641021739008
author Dehnavi, Sajad
Azad, Farahzad Jabbari
Hoseini, Reza Farid
Moazzen, Nasrin
Tavakkol-Afshari, Jalil
Nikpoor, Amin Reza
Salmani, Amir Abbas
Ahanchian, Hamid
Mohammadi, Mojgan
author_facet Dehnavi, Sajad
Azad, Farahzad Jabbari
Hoseini, Reza Farid
Moazzen, Nasrin
Tavakkol-Afshari, Jalil
Nikpoor, Amin Reza
Salmani, Amir Abbas
Ahanchian, Hamid
Mohammadi, Mojgan
author_sort Dehnavi, Sajad
collection PubMed
description BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial. MATERIALS AND METHODS: Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention. RESULTS: Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months (P = 0.001) and also at the end of intervention (P = 0.0001) comparing with the time zero. CONCLUSION: Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion.
format Online
Article
Text
id pubmed-6611180
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-66111802019-07-22 A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial Dehnavi, Sajad Azad, Farahzad Jabbari Hoseini, Reza Farid Moazzen, Nasrin Tavakkol-Afshari, Jalil Nikpoor, Amin Reza Salmani, Amir Abbas Ahanchian, Hamid Mohammadi, Mojgan J Res Med Sci Original Article BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial. MATERIALS AND METHODS: Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention. RESULTS: Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months (P = 0.001) and also at the end of intervention (P = 0.0001) comparing with the time zero. CONCLUSION: Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion. Wolters Kluwer - Medknow 2019-06-25 /pmc/articles/PMC6611180/ /pubmed/31333730 http://dx.doi.org/10.4103/jrms.JRMS_543_18 Text en Copyright: © 2019 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Dehnavi, Sajad
Azad, Farahzad Jabbari
Hoseini, Reza Farid
Moazzen, Nasrin
Tavakkol-Afshari, Jalil
Nikpoor, Amin Reza
Salmani, Amir Abbas
Ahanchian, Hamid
Mohammadi, Mojgan
A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title_full A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title_fullStr A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title_full_unstemmed A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title_short A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
title_sort significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: a placebo-controlled clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611180/
https://www.ncbi.nlm.nih.gov/pubmed/31333730
http://dx.doi.org/10.4103/jrms.JRMS_543_18
work_keys_str_mv AT dehnavisajad asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT azadfarahzadjabbari asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT hoseinirezafarid asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT moazzennasrin asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT tavakkolafsharijalil asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT nikpooraminreza asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT salmaniamirabbas asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT ahanchianhamid asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT mohammadimojgan asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT dehnavisajad significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT azadfarahzadjabbari significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT hoseinirezafarid significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT moazzennasrin significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT tavakkolafsharijalil significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT nikpooraminreza significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT salmaniamirabbas significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT ahanchianhamid significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial
AT mohammadimojgan significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial